Clinical trial market in warmer climes
Facebook Twitter google+ RSS Feed

Clinical trial market in warmer climes

By agencies   |   Friday, 29 July 2005, 07:00 Hrs
Printer Print Email Email
HYDERABAD: India is set to emerge as a major player in the global market for third party clinical trials and a host of companies are increasingly engaging themselves in clinical trials of different magnitudes.

Though clinical trials of biotech and medicinal products for approval purposes are done usually in hospitals in India, there are many companies or agencies such as Ranbaxy, Eli Lilly, Asian Clinical Trials Ltd, among others, which are engaged in clinical trials.

According to industry experts, while the relatively low cost of the entire process in India is major attraction, the opportunities for Indian pharmaceutical and contract research organizations are now set for rise for a variety of reasons.

"The product patent protection will encourage multinational companies to import technology into India to develop new products. Indirectly, this will give boost to clinical trials market," P V Appaji, Executive Director, Pharmaceutical Export Promotion Council (Pharmexil), said.

Experts on SiliconIndia
Santhosh  K
Sr. Soft. Engg.
Oracle India
Nehal Vyas
Sr. Team Lead
Cyberoam Tech.
Rani Malli
Sr. Director
Philips
Sr. Executive
ISB
Vijay Balkrishna Konduskar
Business Consultant
Imans Web Tech
Dr L P  Sharma
Technical Director
NIC
Reena Khanna
Founder
Solitaireworld
Dellas  Asse
sys-network admin
Computer Station
Write your comment now
Submit Reset
SPOTLIGHT